Amicus Therapeutics Correlations
FOLD Stock | USD 8.18 0.12 1.45% |
The current 90-days correlation between Amicus Therapeutics and Dianthus Therapeutics is 0.14 (i.e., Average diversification). The correlation of Amicus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Amicus Therapeutics Correlation With Market
Modest diversification
The correlation between Amicus Therapeutics and DJI is 0.27 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Amicus Stock
0.87 | EQ | Equillium | PairCorr |
0.68 | RAC | Race Oncology | PairCorr |
0.84 | CMB | Cambium Bio | PairCorr |
0.9 | DMAC | DiaMedica Therapeutics | PairCorr |
0.75 | VALN | Valneva SE ADR | PairCorr |
0.62 | 688578 | Shanghai Allist Phar | PairCorr |
0.81 | DNTH | Dianthus Therapeutics | PairCorr |
0.92 | VCYT | Veracyte Sell-off Trend | PairCorr |
0.63 | VERA | Vera Therapeutics | PairCorr |
0.88 | DRUG | Bright Minds Biosciences | PairCorr |
0.82 | DRTS | Alpha Tau Medical | PairCorr |
0.68 | CDIOW | Cardio Diagnostics | PairCorr |
0.92 | DSGN | Design Therapeutics | PairCorr |
0.71 | VIVS | VivoSim Labs, Symbol Change | PairCorr |
0.82 | VRDN | Viridian Therapeutics | PairCorr |
Moving against Amicus Stock
0.89 | DRMA | Dermata Therapeutics | PairCorr |
0.82 | VCEL | Vericel Corp Ord | PairCorr |
0.43 | AVH | Avita Medical | PairCorr |
0.37 | VANI | Vivani Medical | PairCorr |
0.81 | DVAX | Dynavax Technologies | PairCorr |
0.66 | SRZNW | Surrozen Warrant | PairCorr |
0.63 | SABSW | SAB Biotherapeutics | PairCorr |
0.52 | VKTX | Viking Therapeutics | PairCorr |
0.9 | VRAX | Virax Biolabs Group | PairCorr |
0.76 | VRTX | Vertex Pharmaceuticals | PairCorr |
0.68 | ALA | Arovella Therapeutics | PairCorr |
0.51 | VXRT | Vaxart Inc | PairCorr |
0.46 | VPRO | Viropro | PairCorr |
0.37 | KTTAW | Pasithea Therapeutics | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Amicus Stock performing well and Amicus Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Amicus Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
EQ | 9.13 | 3.10 | 0.43 | (0.76) | 5.80 | 21.79 | 103.18 | |||
VALN | 4.02 | 0.90 | 0.20 | 0.23 | 4.07 | 12.27 | 37.71 | |||
DNTH | 3.09 | 0.82 | 0.27 | 0.40 | 2.56 | 7.74 | 25.45 | |||
VCEL | 2.84 | (0.39) | 0.00 | (0.11) | 0.00 | 6.10 | 21.17 | |||
JUMP | 0.90 | 0.46 | 0.00 | (0.68) | 0.00 | 0.00 | 0.00 | |||
VCYT | 2.46 | 0.36 | 0.15 | 0.21 | 2.29 | 5.48 | 20.16 | |||
DRMA | 3.93 | (0.73) | 0.00 | (0.49) | 0.00 | 8.84 | 28.34 |
Amicus Therapeutics Corporate Management
Anthony Sileno | Senior Sciences | Profile | |
David Clark | Chief Officer | Profile | |
Patrik Esq | Global Officer | Profile | |
Michael Keavany | Senior Business | Profile | |
Sbastien Martel | Chief Officer | Profile | |
Patrik Florencio | Global VP | Profile |